CTLA4 sirna

CTLA4 siRNA (Mouse)

Cat. Num. AAA8206364

• Gene Names: Ctla4; Cd152; Ly-56; Ctla-4
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: CTLA4; CTLA4 siRNA (Mouse); CD152; Cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; CTLA-4; CD antigen CD152; CTLA4 sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: CTLA4 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 223

• Applicable Applications for CTLA4 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse CTLA4 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for CTLA4 sirna

siRNA to inhibit CTLA4 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 31981847
• NCBI GeneID: 12477
• NCBI Accession #: NP_033973.2
• NCBI GenBank Nucleotide #: NM_009843.4
• UniProt Accession #: P09793; Q9QZZ7
• Molecular Weight: 24,993 Da
• NCBI Official Full Name: cytotoxic T-lymphocyte protein 4 isoform 1
• NCBI Official Synonym Full Names: cytotoxic T-lymphocyte-associated protein 4
• NCBI Official Symbol: Ctla4
• NCBI Official Synonym Symbols: Cd152; Ly-56; Ctla-4
• NCBI Protein Information: cytotoxic T-lymphocyte protein 4
• UniProt Protein Name: Cytotoxic T-lymphocyte protein 4
• Protein Family: Cytotoxic T-lymphocyte protein
• UniProt Gene Name: Ctla4
• UniProt Synonym Gene Names: Cd152; CTLA-4
• UniProt Entry Name: CTLA4_MOUSE

NCBI Description

This gene is a member of the immunoglobulin superfamily, and encodes a protein that functions as a negative regulator of T-cell responses. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Aug 2013]

Uniprot Description

CTLA-4: Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE). SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system. Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism. Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12). A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3). It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Membrane protein, integral; Immunoglobulin superfamily

Cellular Component: Golgi apparatus; membrane; perinuclear region of cytoplasm; integral to membrane; plasma membrane; clathrin-coated endocytic vesicle; external side of plasma membrane

Biological Process: B cell receptor signaling pathway; negative regulation of T cell proliferation; negative regulation of regulatory T cell differentiation; positive regulation of apoptosis; immune system process; negative regulation of immune response; immune response; negative regulation of B cell proliferation; response to DNA damage stimulus